Consider both your practice’s needs and the long-term viability of the technology when selecting an EHR system.
Drug Updates: Citalopram hydrobromide, Statins, and More
Information on new approvals and medication safety
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.
New Diagnostic Criteria for Axial Spondylarthritis
New name and classification criteria for ankylosing spondylitis may help with earlier diagnosis and treatment.
Data-Driven, Optimal Patient Care and Clinical Research
Expanded opportunities to advance rheumatology will be offered by ACR’s ongoing registry efforts
Quality Measurement Improves Rheumatology Outcomes
Innovations in health information technology can have significant impact
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
Medical Device Safety Concerns Rheumatologists
Are recent controversies over metal-on-metal hip replacements and an IOM report cause for worry?
FDA Seeks Comments on Drug Shortages
As reported last month (“Rheumatologists Struggle with Drug Shortages,” October 2011, p. 51), a bill (S. 296) proposed in the U.S. Senate would require drug manufacturers to notify the U.S. Food and Drug Administration (FDA) of factors that might lead to a drug shortage.
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »